How did EXAS outperform forecasts in Q4 2024?

Exact Sciences Corporation (EXAS) outperformed forecasts in Q4 2024 primarily due to stronger-than-expected revenue, which increased by 10.3% year-on-year to $713.4 million. This growth was driven by the company's focus on cancer screening and diagnostic tests. The revenue figures were bolstered by a strategic partnership aimed at integrating MRD (Minimal Residual Disease) testing into precision cancer care. This collaboration, which involved collecting real-world data from diverse patients, underscored EXAS's commitment to innovation and its position as a leader in the diagnostic sector. The company's preliminary financial results for Q4 2024 indicated an expected revenue of $713 million, which aligned closely with analysts' estimates and reflected a robust market presence.

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|EXAS|EXAS.O|Exact Sciences|2024 Q1|-48.653423419778555|-1.10228E8|186|
|EXAS|EXAS.O|Exact Sciences|2024 Q2|80.49021301804359|-1.5808E7|186|
|EXAS|EXAS.O|Exact Sciences|2024 Q3|-4915.617128463476|-3.8236E7|186|
|EXAS|EXAS.O|Exact Sciences|2024 Q4|-1637.3005666519311|-8.64585E8|186|

|code|Ticker|Name|Date|Closing Price|market_code|
|---|---|---|---|---|---|
|EXAS|EXAS.O|Exact Sciences|20250403|44.28|186|